Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of NIM-1324 in healthy volunteers
NCT05019950Phase 1Completed
- Sponsor
- NImmune Biopharma
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) comparing NIM-1324 with Placebo (2 arms). Primary endpoint: Safety and Tolerability. Started Oct 2021; status: completed.
02
Drugs
NIM-1324
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05019950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05019950.